KRYS Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 0.91%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Krystal Biotech, Inc. has a consensus price target of $314.00, signalling upside risk potential of 20.33%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Krystal Biotech, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Amicus Therapeutics, Inc..

Krystal Biotech, Inc. has a beta of 0.540, which suggesting that the stock is 46.017% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Krystal Biotech, Inc.'s net income of $51.4M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.41x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.22x versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 21.74%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Krystal Biotech, Inc. has a consensus price target of $314.00, signalling upside risk potential of 20.33%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that Krystal Biotech, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Krystal Biotech, Inc. has a beta of 0.540, which suggesting that the stock is 46.017% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Krystal Biotech, Inc.'s net income of $51.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.41x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.22x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding Corp. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of --. Krystal Biotech, Inc.'s return on equity of 19.22% beat Scholar Rock Holding Corp.'s return on equity of -134.52%.

Krystal Biotech, Inc. has a consensus price target of $314.00, signalling upside risk potential of 20.33%. On the other hand Scholar Rock Holding Corp. has an analysts' consensus of $57.43 which suggests that it could grow by 14.83%. Given that Krystal Biotech, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Krystal Biotech, Inc. is more attractive than Scholar Rock Holding Corp..

Krystal Biotech, Inc. has a beta of 0.540, which suggesting that the stock is 46.017% less volatile than S&P 500. In comparison Scholar Rock Holding Corp. has a beta of 0.676, suggesting its less volatile than the S&P 500 by 32.396%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Scholar Rock Holding Corp. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are larger than Scholar Rock Holding Corp. quarterly revenues of --. Krystal Biotech, Inc.'s net income of $51.4M is higher than Scholar Rock Holding Corp.'s net income of -$91M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.41x while Scholar Rock Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.22x versus 72.82x for Scholar Rock Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of -4132.24%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Stoke Therapeutics, Inc.'s return on equity of -2.19%.

Krystal Biotech, Inc. has a consensus price target of $314.00, signalling upside risk potential of 20.33%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $45.10 which suggests that it could grow by 37.75%. Given that Stoke Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.540, which suggesting that the stock is 46.017% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.802%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $1.4M. Krystal Biotech, Inc.'s net income of $51.4M is higher than Stoke Therapeutics, Inc.'s net income of -$57.9M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.41x while Stoke Therapeutics, Inc.'s PE ratio is 51.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.22x versus 10.42x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.